This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors.
The “Berlin patient” was cured from HIV after getting new T-cells that did not have a coreceptor the HIV could bind to. The mechanism of action for this product is in principle the same – HIV will be unable to form a binding to the co-receptors CCR5 and CXCR4 and consequently cannot re-infect new T-cells.
This product will also cause a draining of the reservoirs by allowing the other vaccines to attack visible HIV infected T-cells. This property is unique to CRX and is in contrast to ART which hides the reservoirs and leave them intact and fit for new HIV production once ART is stopped.
The 3rd vaccine – Vacc-CRX is targeting neutralizing epitopes.
Lead optimization and drug characterization with PoP will be established within the next 6 – 9 months.